Evaluation of catastrophic health expenditure risk due to measles in Nigeria.
Catastrophic health expenditure
Nigeria
measles
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
29
4
2022
medline:
23
7
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Measles can have a substantial negative impact not only on people's health but also on their finances, especially in developing countries. This study evaluates the household risk of catastrophic health expenditure (CHE) due to measles, according to regions and wealth quintiles. The CHE risk due to measles was computed based on (1) the likelihood of health service utilization to treat measles, (2) out-of-pocket (OOP) expenditure and indirect costs associated with disease treatment, and (3) household consumption expenditures. I derived the CHE risk associated with measles, conditional on contracting the disease, across regions and wealth quintiles in Nigeria, using secondary data sources for health-care utilization, OOP expenditures, and consumption expenditures. There was a large variation in CHE risk according to regions and wealth quintiles. Among the poorest households, those in the northeast and northwest would have the highest risk of CHE, up to 17%, while those in the southwest would have the lowest risk of 5%. For all regions, as the wealth increases, the CHE risk would decrease. There would be zero or very little CHE risk among the richest households in any regions. Given the proven efficacy of measles vaccines, immunizations can prevent households, especially poorer households in northeast and northwest regions, from facing the CHE risk due to measles.
Identifiants
pubmed: 35483039
doi: 10.1080/21645515.2022.2065836
pmc: PMC9302492
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2065836Références
Vaccine. 2019 Sep 24;37(41):6039-6047
pubmed: 31471147
BMJ Glob Health. 2017 Jan 18;2(1):e000166
pubmed: 28589003
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705
pubmed: 33180759
Risk Anal. 2016 Jul;36(7):1357-82
pubmed: 26249331
Health Aff (Millwood). 2018 Feb;37(2):316-324
pubmed: 29401021
Vaccine. 2003 Jan 30;21(7-8):596-600
pubmed: 12531324
BMJ Open. 2021 Apr 24;11(4):e044969
pubmed: 33895715
Health Aff (Millwood). 2016 Feb;35(2):199-207
pubmed: 26858370
Pediatr Infect Dis J. 2012 Nov;31(11):e189-95
pubmed: 22668806
BMJ Glob Health. 2018 Apr 09;3(2):e000613
pubmed: 29662691
Cost Eff Resour Alloc. 2009 Jan 22;7:3
pubmed: 19161598
Am J Trop Med Hyg. 2012 Jan;86(1):52-7
pubmed: 22232451